• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCardia wins CE Mark renewal for Helix, Morph catheters

October 9, 2019 By Sean Whooley

BioCardiaBioCardia (OTC:BCDA) said yesterday that it won CE Mark renewal for its Helix biotherapeutic delivery catheter and Morph universal deflectable guide catheter for delivery of biotherapeutics to the heart.

With the renewed CE Mark, BioCardia said it can continue supporting partners outside the U.S. and move forward with commercial sales of the Helix and Morph systems in Europe and other locations that recognize the CE Mark through May 2024.

The Helix system, which includes the Morph guide product, is currently under evaluation in the U.S. Phase III pivotal CardiAMP heart failure trial. The CardiAMP cell therapy candidate is designed to deliver a patient’s own bone marrow cells to the heart in a minimally invasive procedure to potentially stimulate the body’s natural healing process.

The FDA approved the trial in January 2018 and in August 2018, and in August 2018, BioCardia announced data showing that the first 10-patient cohort of patients from the 260-patient trial saw improvements in their six-minute walk distance and 40% of patients improved by one class in the New York Heart Association Heart Failure Class scoring system.

BioCardia also partners with other companies to provide the Helix systems and support to programs looking for therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

“Renewal of the CE Mark for our innovative biotherapeutic delivery products ensures that we can continue participating in a variety of biotherapeutic research programs with the potential to drive the field forward and respond to very ill patients,” CEO Peter Altman said in prepared remarks. “In light of sweeping European regulatory changes associated with the transition from the MDD directive to the new MDR regulation, it has been a challenging time for both notified bodies, who are working to become certified to grant CE Mark under the new system, and for companies, who are trying to meet the new requirements and move their CE Mark applications forward. It is a significant achievement for BioCardia to have received CE Mark renewal in this environment, when many other companies are struggling to do the same or even abandoning the region.”

Shares of BCDA were up 6.4% to $3.51 per share in late-morning trading today.

Filed Under: Cardiovascular, Featured, Regenerative Medicine, Regulatory/Compliance Tagged With: BioCardia

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS